MAP Kinase 2, inactive, Recombinant, Mouse (Mitogen-activated Protein Kinase 2, MAPK 2, MAPK2, Extracellular Signal-regulated Kinase 2, ERK2, ERK-2, ERK, ERT1, MAP Kinase Isoform p42, Mitogen-activated Protein Kinase 1, MAP Kinase 1, MAPK 1, Mapk1, Mapk, p42mapk, p42-MAPK, Prkm1, PRKM2)

Cat# M2362-01M-100ug

Size : 100ug

Brand : US Biological



M2362-01M MAP Kinase 2, inactive, Recombinant, Mouse (Mitogen-activated Protein Kinase 2, MAPK 2, MAPK2, Extracellular Signal-regulated Kinase 2, ERK2, ERK-2, ERK, ERT1, MAP Kinase Isoform p42, Mitogen-activated Protein Kinase 1, MAP Kinase 1, MAPK 1, Mapk1, Mapk, p42mapk, p42-MAPK, Prkm1, PRKM2)

Swiss Prot
P49138
Grade
Purified
Shipping Temp
Dry Ice
Storage Temp
-70°C

Stress-activated serine/threonine-protein kinase involved in cytokine production, endocytosis, reorganization of the cytoskeleton, cell migration, cell cycle control, chromatin remodeling, DNA damage response and transcriptional regulation. Following stress, it is phosphorylated and activated by MAP kinase p38-alpha/MAPK14, leading to phosphorylation of substrates. Phosphorylates serine in the peptide sequence, Hyd-X-R-X2-S, where Hyd is a large hydrophobic residue. Phosphorylates ALOX5, CDC25B, CDC25C, CEP131, ELAVL1, HNRNPA0, HSP27/HSPB1, KRT18, KRT20, LIMK1, LSP1, PABPC1, PARN, PDE4A, RCSD1, RPS6KA3, TAB3 and TTP/ZFP36. Phosphorylates HSF1; leading to the interaction with HSP90 proteins and inhibiting HSF1 homotrimerization, DNA-binding and transactivation activities (By similarity).

Full length inactive recombinant protein corresponding to mouse ERK2/MAPK2, with mutation on lysine52 to arginine, fused with a N-terminal 6X -HisTag, expressed in E. coli. Swiss/Uniport: P49138

Applications:
A suitable substrate of MEK1. Other applications not tested.

Recommended Dilution:
Optimal dilutions to be determined by the researcher.
Storage and Stability:
Aliquot to avoid repeated freezing and thawing and store at -70°C. Aliquots are stable for 6 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Applications
Source: Recombinant, E. coli|Purity: ≥90%|Concentration: As Reported |Form: Supplied as a liquid in 45mM Tris-HCl, pH 8.0, 124mM sodium chloride, 2.4mM potassium chloride, 3mM DTT, 10% glycerol. Variable amount of imidazole.||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Form
Supplied as a liquid in 45mM Tris-HCl, pH 8.0, 124mM sodium chloride, 2.4mM potassium chloride, 3mM DTT, 10% glycerol. Variable amount of imidazole.
Purity
≥90%
References
1. Mitsushima,M. et al Cell Res. 313 (9), 1830- 1838 (2007)|2. Wille,L. et al. Mol. Immunol. 44 (12), 3085- 3091 (2007)